Epigenetic And Genetic Approaches In Cancer Epidemiology And Risk Assessment | 4853
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The National Institutes of Health (NIH) has initiated the Epigenomics Roadmap Program (http://www.roadmapepigenomics.
org/) which is comprised of five major initiatives: Reference Epigenome Mapping Centers, Epigenomic Data Analysis and
Coordinating Centers, Technology Development in Epigenetics, Discovery of Novel Epigenetic Marks, Epigenomics of Human
Health and Diseases. This program proposes that the origins of health and susceptibility to disease are the result of epigenetic
regulation of the genetic information. Specifically, epigenetic mechanisms that control stem cell differentiation and organogenesis
contribute to the biological response to environmental and other factors in the form of stimuli that contribute in disease
development. Epigenetic and genetic approaches in cancer epidemiology and risk assessment will be discussed. Epidemiology is
the scientific study of the causes and distribution of disease in populations. The National Cancer Institute?s Epidemiology and
Genetics Research Program (EGRP), in the Division of Cancer Control and Population Sciences, provides opportunities for
investigators to increase understanding of cancer causes and prevention in human populations. EGRP supports research in four
areas: (1) Clinical and translational epidemiology, including factors that influence development of cancer among persons with
underlying diseases and conditions; the progression, recurrence, and mortality from cancer; and development of new primary
cancers; (2) Host susceptibility factors that influence personal susceptibility to cancer in humans, such as genetic, epigenetic,
immunological, hormonal, and biological pathways; and social, cultural, racial, and ethnic factors; (3) Methods and technologies
for epidemiologic data collection, study design and analysis, and development and adaptation of laboratory and technical
approaches for large studies in human populations; (4) Modifiable risk factors to reduce cancer risk in humans, such as diet and
nutrition; alcohol; physical activity and energy balance; tobacco; infectious diseases; physical and chemical agents; and medical
exposures, including medications and treatments. Different funding mechanisms of grants and contracts, and collaboration
opportunities will be discussed.
Mukesh Verma is a Program Director and Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genetics Research Program
(EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health
(NIH). Before coming to the DCCPS, he was a Program Director in the Division of Cancer Prevention (DCP), NCI, providing direction in the areas
of biomarkers, early detection, risk assessment and prevention of cancer, and cancers associated with infectious agents. Dr. Mukesh Verma holds
a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He did postdoctoral research at George Washington University and
was a faculty member at Georgetown University. He has published 116 research articles and reviews and edited three books in cancer epigenetics
and epidemiology field.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals